On July 5, 2026 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, reported that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Developed from InnoCare’s in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker. This design enables significantly enhanced tumor-killing effects with improved stability and safety.

CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for the ADC therapy, which can be developed for the treatment of gastrointestinal cancers, including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary tract cancer. Currently, there are no approved CDH17 targeted ADCs globally.

Dr. Jasmine Cui, Co-Founder, Chairwoman, and CEO of InnoCare, said, "I am pleased to see the clinical development progress of our second ADC drug, following ICP-B794, our novel ADC targeting B7-H3. Through our innovated platform, we have developed multiple ADC candidates with strong tumor killing effects and an excellent safety profile, which will offer better treatment options for cancer patients globally."

(Press release, InnoCare Pharma, JUL 5, 2026, View Source [SID1234669065])